Mete, B. And Gençer, S. 2022. Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ E mtric itabi ne, Hivent® to Brand Name, Truvada® in HIV-Infected Patients. Cerrahpaşa Medical Journal , vol.46, no.3 , 238-244.

Mete, B., & Gençer, S., (2022). Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ E mtric itabi ne, Hivent® to Brand Name, Truvada® in HIV-Infected Patients. Cerrahpaşa Medical Journal , vol.46, no.3, 238-244.

Mete, Bilgül, And Serap GENÇER. "Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ E mtric itabi ne, Hivent® to Brand Name, Truvada® in HIV-Infected Patients," Cerrahpaşa Medical Journal , vol.46, no.3, 238-244, 2022

Mete, Bilgül And Gençer, Serap. "Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ E mtric itabi ne, Hivent® to Brand Name, Truvada® in HIV-Infected Patients." Cerrahpaşa Medical Journal , vol.46, no.3, pp.238-244, 2022

Mete, B. And Gençer, S. (2022) . "Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ E mtric itabi ne, Hivent® to Brand Name, Truvada® in HIV-Infected Patients." Cerrahpaşa Medical Journal , vol.46, no.3, pp.238-244.

@article{article, author={Bilgül Mete And author={Serap GENÇER}, title={Non-inferiority of Generic Tenofovir Disoproxil Fumarate/ E mtric itabi ne, Hivent® to Brand Name, Truvada® in HIV-Infected Patients}, journal={Cerrahpaşa Medical Journal}, year=2022, pages={238-244} }